Colin Powers, Brielle Corrente, Jennifer Joyce, William Stein, Shelly Polydor, Vikraman Gunabushanam, Ajai Khanna, Fernanda P. Silveira, Ruy J. Cruz Jr.
{"title":"COVID-19对肠道移植受者的不断变化的影响：单中心体验。","authors":"Colin Powers, Brielle Corrente, Jennifer Joyce, William Stein, Shelly Polydor, Vikraman Gunabushanam, Ajai Khanna, Fernanda P. Silveira, Ruy J. Cruz Jr.","doi":"10.1111/ctr.70065","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>There has been significant concern about coronavirus disease 2019 (COVID-19) among transplant recipients, particularly those who are highly immunosuppressed. Several studies have analyzed the impact of COVID-19 on different solid organ transplant patients. However, few isolated case reports of COVID-19 in intestinal and multivisceral transplant (ITx and MVTx) recipients are available in the literature. We report the first single-center study evaluating the clinical course and outcome of COVID-19 in ITx/MVTx recipients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Adult patients (age ≥ 18 years) with confirmed cases of COVID-19 between February 2020 and February 2024 were included in this study.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Twelve of the 67 (17.9%) ITx/MVTx recipients followed at our center had COVID-19. Seven patients (58%) were female, and the median age at diagnosis was 47 years (range: 31–68 years). The average time from transplantation to COVID-19 was 89 months (range: 14–215 months). Nine patients (75%) required hospitalization; three of them were admitted to the intensive care unit (ICU) and required ventilator support. One patient had COVID-19 on two different occasions. Treatment modalities consisted of monoclonal antibody treatment (<i>n</i> = 5), of antiviral therapy (<i>n</i> = 4), and steroid monotherapy (<i>n</i> = 1). Three patients received combination therapy. Three patients (25%) developed irreversible respiratory failure and died after prolonged ventilator use.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our data suggested a possible increase in the incidence of COVID-19 in ITx and MVTx recipients with an unchanged mortality rate despite the use of vaccines and new therapeutic modalities. Further multicenter studies are needed to analyze the real impact of COVID-19 on this unique population.</p>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 1","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683853/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evolving Impact of COVID-19 on Intestinal Transplant Recipients: A Single-Center Experience\",\"authors\":\"Colin Powers, Brielle Corrente, Jennifer Joyce, William Stein, Shelly Polydor, Vikraman Gunabushanam, Ajai Khanna, Fernanda P. Silveira, Ruy J. Cruz Jr.\",\"doi\":\"10.1111/ctr.70065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>There has been significant concern about coronavirus disease 2019 (COVID-19) among transplant recipients, particularly those who are highly immunosuppressed. Several studies have analyzed the impact of COVID-19 on different solid organ transplant patients. However, few isolated case reports of COVID-19 in intestinal and multivisceral transplant (ITx and MVTx) recipients are available in the literature. We report the first single-center study evaluating the clinical course and outcome of COVID-19 in ITx/MVTx recipients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Adult patients (age ≥ 18 years) with confirmed cases of COVID-19 between February 2020 and February 2024 were included in this study.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Twelve of the 67 (17.9%) ITx/MVTx recipients followed at our center had COVID-19. Seven patients (58%) were female, and the median age at diagnosis was 47 years (range: 31–68 years). The average time from transplantation to COVID-19 was 89 months (range: 14–215 months). Nine patients (75%) required hospitalization; three of them were admitted to the intensive care unit (ICU) and required ventilator support. One patient had COVID-19 on two different occasions. Treatment modalities consisted of monoclonal antibody treatment (<i>n</i> = 5), of antiviral therapy (<i>n</i> = 4), and steroid monotherapy (<i>n</i> = 1). Three patients received combination therapy. Three patients (25%) developed irreversible respiratory failure and died after prolonged ventilator use.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Our data suggested a possible increase in the incidence of COVID-19 in ITx and MVTx recipients with an unchanged mortality rate despite the use of vaccines and new therapeutic modalities. Further multicenter studies are needed to analyze the real impact of COVID-19 on this unique population.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10467,\"journal\":{\"name\":\"Clinical Transplantation\",\"volume\":\"39 1\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683853/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70065\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70065","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Evolving Impact of COVID-19 on Intestinal Transplant Recipients: A Single-Center Experience
Background
There has been significant concern about coronavirus disease 2019 (COVID-19) among transplant recipients, particularly those who are highly immunosuppressed. Several studies have analyzed the impact of COVID-19 on different solid organ transplant patients. However, few isolated case reports of COVID-19 in intestinal and multivisceral transplant (ITx and MVTx) recipients are available in the literature. We report the first single-center study evaluating the clinical course and outcome of COVID-19 in ITx/MVTx recipients.
Methods
Adult patients (age ≥ 18 years) with confirmed cases of COVID-19 between February 2020 and February 2024 were included in this study.
Results
Twelve of the 67 (17.9%) ITx/MVTx recipients followed at our center had COVID-19. Seven patients (58%) were female, and the median age at diagnosis was 47 years (range: 31–68 years). The average time from transplantation to COVID-19 was 89 months (range: 14–215 months). Nine patients (75%) required hospitalization; three of them were admitted to the intensive care unit (ICU) and required ventilator support. One patient had COVID-19 on two different occasions. Treatment modalities consisted of monoclonal antibody treatment (n = 5), of antiviral therapy (n = 4), and steroid monotherapy (n = 1). Three patients received combination therapy. Three patients (25%) developed irreversible respiratory failure and died after prolonged ventilator use.
Conclusions
Our data suggested a possible increase in the incidence of COVID-19 in ITx and MVTx recipients with an unchanged mortality rate despite the use of vaccines and new therapeutic modalities. Further multicenter studies are needed to analyze the real impact of COVID-19 on this unique population.
期刊介绍：
Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored.
Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include:
Immunology and immunosuppression;
Patient preparation;
Social, ethical, and psychological issues;
Complications, short- and long-term results;
Artificial organs;
Donation and preservation of organ and tissue;
Translational studies;
Advances in tissue typing;
Updates on transplant pathology;.
Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries.
Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
